Latanoprost Fdc International

Latanoprost, the active ingredient in Latanoprost Fdc International, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, helping to preserve visual function.

GNH USA supplies Latanoprost Fdc International as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets.

Latanoprost is used in the management of ocular conditions that require reduction of intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. Ocular hypertension: reduces pressure to prevent conversion to glaucoma. Secondary glaucoma (e.g., pseudoexfoliative): helps control pressure when other therapies are insufficient.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Eye irritation or foreign‑body sensation. - Blurred vision shortly after instillation. - Increased eyelash length and thickness. - Darkening of the iris color. - Periocular skin hyperpigmentation.

Serious or Rare Side Effects: - Severe anterior uveitis or iritis. - Allergic contact dermatitis of the eyelid. - Significant visual acuity loss. - Ocular infection secondary to compromised surface. - Periorbital fat atrophy leading to cosmetic changes.

Before using Latanoprost, consider the following safety measures.

Monitor intra‑ocular pressure regularly: ensure therapeutic effect and detect over‑reduction. Avoid contact lens wear for at least 15 minutes after instillation: reduce drug absorption by the lens. Assess for pre‑existing ocular infections or inflammation: avoid exacerbation. Caution in patients with corneal endothelial disease: may affect healing. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at room temperature: keep in original container, protect from moisture and light.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: may increase risk of ocular irritation. - Recent ocular surgery: can impair wound healing. - Use with potent topical corticosteroids: may reduce efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intra‑ocular pressure lowering effect; monitor pressure. - Carbonic anhydrase inhibitor eye drops: potential for excessive pressure reduction. - Systemic NSAIDs: may modestly affect prostaglandin pathways; observe for changes in response.